An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Skyrizi

Chemical Namerisankizumab-rzaa
Dosage FormInjection (subcutaneous; 75 mg/0.83 mL)
Drug ClassMonoclonal antibodies
SystemSkin
CompanyAbbVie Inc.
Approval Year2019

Indication

  • Skyrizi is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Last updated on 2/5/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Skyrizi (risankizumab-rzaa) Prescribing Information2020Abbie
Document TitleYearSource
Clinical review report: risankizumab (skyrizi) (AbbVie).2019CADTH
Pharmacoeconomic review report: risankizumab (skyrizi) (AbbVie).2019CADTH
Risankizumab for treating moderate to severe plaque psoriasis.2019NICE
Document TitleYearSource
Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis.2020Cochrane Database of Systematic Reviews
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.2020Journal of the European Academy of Dermatology and Venereology
Short-term effectiveness of biologics in patients with moderate-to -severe plaque psoriasis: a systematic review and network meta-analysis.2020Journal of Dermatological Science
Efficacy and safety of risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis.2020Dermatologic Therapy
Document TitleYearSource
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.2019Journal of the American Academy of Dermatology